Targeted therapy of renal cancer : what is its implementation

Targeted therapy of renal cancer - this is one of the newest methods of treatment of malignant tumors, which builds on principles of trust influence the basic molecular mechanisms that underlie the pathology.

invention of an entirely new method of therapy in oncology realized by a plurality of theoretical studies, which were implemented in the seventies of the twentieth century.

In 1971, Folkman scientist spoke about the phenomenon of carcinogenesis in oncology.Swelling during sprawl needs to shape its vascular network.Upon reaching the size of 2 mm in diameter, it can not sformirovyvaetsya without forming new blood vessels.In this regard, the benign set of cells for the human tumor begins to transform into a malignant cell system having the ability to spread metastases.Due to the emergence of new blood vessels increase in the number of malignant cells carries exponential, causing rapid increase in tumors.

This is important! addition in the seventies was first described the mechanism of regulation of

cell proliferation.It lies in the fact that the increase in tumors occurs after development of mutations in several genes involved in cell proliferation.

turns that completely new target for anti-tumor agents of the invention have been developed.These drugs are known as Targeted.

Worldwide currently doctors fix an increased incidence of malignant tumors of kidney damage.Such statistics are directly related to the overall increase in the destruction of people oncology, as well as with the improvement of diagnostic processes which help to establish the disease even in the early stages.More recently people are diagnosed with metastatic renal oncology was doomed - because chemotherapy, radiation, hormone therapy did not bring any results in renal cancer.In the last decade, much has changed, especially in the approach to the implementation of drug therapy.Patients are able to prolong life and improve the well-being thanks to new drugs that are targeted.

main characteristics of treatment

targeted therapies for kidney cancer affect tumor slightly different compared to the usual methods.It provoked the death of malignant cells and almost no effect on healthy tissues, so do not cause serious adverse effects.In oncology

this treatment is based on the studying and understanding the mechanisms of correct molecular structure of the tumor as well as the invention, medicaments which directly act on specific molecules responsible for the growth and progression of tumor cells.

Targeted drugs can be used alone or in combination with traditional treatment oncology kidney - with radiotherapy or chemotherapy. newest progressive treatment is often used as a means of prevention of relapse prevention.

targeted treatment inhibitors angioneogenesis

For proper growth tumors it must develop new blood vessels, for him to the tissues of cancer cells will be supplied with oxygen and nutrients.Tumor cells are capable of producing a lot of growth factors that would stimulate the emergence of new vessels.This process is called angioneogenesis and influence angioneogenesis inhibitors significantly slows down the malignant process.

This is important! Mechanisms of influence of targeted medicines are different from the effects of chemotherapeutic agents as first violate the proliferation of the tumor at the molecular level and the minimum impact on healthy tissue.

treatment effect and its toxic effects

targeted treatment can prevent the reproduction and spread of the tumor cells, so its toxic effects on healthy cells in the human body is much less in comparison with cytotoxic therapy.

The incidence of serious adverse effects remains relatively low.There neutropenia, thrombocytopenia, a violation of the digestive functions - indigestion and an increased concentration of amylase.Damage to the epidermis will be manifested in the form of hand-foot syndrome in 5% of cases.In some cases, developing hypertension, and most complications easily stoped by reducing the dosage of drugs.

duration of treatment and the dosage used:

appointed standard dose of 50 mg of the drug is considered to be a day for four weeks.Then, a break is made in the two weeks period.With the development of serious side effects, the dosage is reduced to 37% or up to 25 mg, and subsequent dose reduction is meaningless.

possibility of combining with other types of treatment

In accordance with the action of cytostatic agents, and are out of sensitivity to them in cancer cells, their simultaneous application of targeted drugs will not work.

Alternatively, you can talk about the association of targeted funds with a similar, but slightly different mechanism of action.Simultaneous influence of the various targets in the body contributes to the effectiveness of the treatment as a whole.

Like this?Share with friends and acquaintances: